Tegoprazan
Gastroesophageal Reflux Disease (GERD)
NDA SubmittedActive
Key Facts
Indication
Gastroesophageal Reflux Disease (GERD)
Phase
NDA Submitted
Status
Active
Company
About Sebela Pharmaceuticals
Sebela Pharmaceuticals is a private, commercial-stage biopharmaceutical company founded in 2014 and headquartered in Braintree, Massachusetts. The company operates with a dual focus: maintaining a leading position in the gastroenterology market through its affiliate Braintree and driving innovation in women's health via its Sebela Women's Health division. Its near-term value drivers include the FDA review of tegoprazan for GERD and the recent licensing of its hormone-free IUD, MIUDELLA®, to Organon, while its pipeline suggests a commitment to sustained growth in its core therapeutic areas.
View full company profileTherapeutic Areas
Other Gastroesophageal Reflux Disease (GERD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Anti-Reflux Band Mucosectomy (ARBM) | Endolastic | Pre-clinical |
| Omega PF™ | Aplos Medical | Pre-clinical |